NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Peptide testing

Ordered GHK-Cu from Lumira? Mail in a sample (US only) and let us test it.

Test my supply
+16 more ↓
89%
Finnrick rating
#25 of 156 GHK-Cu vendors
12 of 13 classifiable tests passed
natural 92% · customers 4.5★ (15)
methodology · Purity focus
Finnrick analysis · GHK-Cu

Lumira GHK-Cu has a recent severe outlier: after a long run of 99.7-99.9% purity passes, the Oct. 30 sample showed 50.6% purity, -47% fill, no batch ID, and no identity result. The key question is whether it is isolated or a trend.

methodology →
vendor intelligence report
Vendor Intelligence Report: Lumira

Corporate and domain records trace Lumira through Peptaura, dead direct storefronts and a new Welon/ABT layer with unresolved ownership. The report maps the registry mismatch, payment rails and promoter-code network behind the catalog.

41 pages6 risk factors assessed12 Nov 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cuselected
$0.10
89%
13
2
Retatrutide
$1.71
79%
34
3
Tirzepatide
$0.74
75%
15
4
Ipamorelin
$1.37
57%
4
5
hCG
-
57%
5
6
GLOW
$0.57
50%
3
7
Tesamorelin
$3.40
49%
8
8
HGH
-
44%
5
9
TB-500
$2.45
42%
6
10
BPC-157
$1.18
41%
8
11
MOTS-c
$1.22
33%
4
12
CJC-1295
$5.18
31%
2
13
NAD+
$0.03
20%
5
14
Wolverine
$1.76
20%
3
15
CJC-IPA
$1.79
-
0
16
DSIP
$0.96
-
0
17
Epithalon
$0.64
-
0
18
Glutathione
$0.01
-
0
19
KPV
$0.95
-
0
20
Melanotan II
$0.82
-
0
21
Pinealon
$0.90
-
0
22
PT-141
$1.11
-
0
23
Sermorelin
$3.88
-
0
24
SS-31
$0.30
-
0
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%23 Apr 2026: 90%26 Apr 2026: 90%6 May 2026: 91%8 Jun 2026: 91%15 Jun 2026: 92%1 Jul 2026: 92%13 Jul 2026: 93%3 Aug 2026: 93%5 Aug 2026: 93%5 Aug 2026: 94%5 Aug 2026: 94%6 Oct 2026: 93%30 Oct 2026: 89%15 Nov 2026: current 89%90%93%89%Apr 26Nov 26
Showing GHK-Cu tests only
Peptide testing

Ordered GHK-Cu from Lumira? Mail in a sample (US only) and let us test it.

Test my supply
Lumira GHK-Cu test history
COA-backed lab tests
1-10 of 13

About Lumira test results from Finnrick

Lumira is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 14 peptides and 115 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Lumira peptides in this dataset are BPC-157 (8 tests), CJC-1295 (2 tests) and GHK-Cu (13 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 115 recent tests. It also includes 2 corrections related to this vendor.

Corrections
2026-08-04
Lab correction
The original Certificate of Analysis (COA 209392) incorrectly identified the sample as **Tirzepatide** instead of the correct compound, **BPC-157**. The testing laboratory subsequently reissued the Certificate of Analysis as **COA 209656**, correcting the sample identification. The updated COA has been used to replace the incorrect information.
2026-07-26
Finnrick data entry
The COA data was corrected from 56.8 to 568 following identification of a probable parsing error during data extraction. As a result of this correction, the calculated score was updated from 3.5 to 4.1.
Peptide testing

Ordered GHK-Cu from Lumira? Mail in a sample (US only) and let us test it.

Test my supply